INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 217
MOLECULAR MECHANISMS OF DEVELOPMENT AND THERAPEUTIC
PERSPECTIVES OF OVARIAN CANCER
Masharifov Khurshidbek Shomurod ugli
2nd-year student of the Faculty of General Medicine,
Urgench Branch of Tashkent Medical Academy.
Email:
khurshidbekmasharifov5@gmail.com
Rozimova Etibor Bakhtiyarovna
,
Assistant of the Department of Anatomy,
Urgench Branch of Tashkent Medical Academy.
Email: etibor8484@gmail.com
Madrimova Aziza Gaibnazarovna
Dean of the Dentistry faculty, Head of the Registrar's Office
Tashkent medical academy Urgench branch. Email:
Annotation:
In this study, the molecular mechanisms of ovarian cancer development and
promising therapeutic approaches were investigated. Genetic and epigenetic factors contributing
to tumor cell transformation were analyzed, including mutations in BRCA1/2, TP53, and PTEN
genes, as well as disruptions in DNA repair processes. Special attention was given to the role of
signaling pathways such as PI3K/AKT/mTOR, WNT/β-catenin, and NOTCH in tumor
progression. The study examined modern therapeutic strategies, including the use of PARP
inhibitors, monoclonal antibodies, immunotherapy, and RNA interference. The findings confirm
the relevance of further research into the molecular mechanisms of carcinogenesis to develop
more effective personalized treatments for ovarian cancer.
Keywords:
ovarian cancer, molecular mechanisms, genetic mutations, signaling pathways,
epigenetics, targeted therapy, PARP inhibitors, immunotherapy, personalized medicine.
INTRODUCTION
Ovarian cancer is one of the most aggressive and difficult-to-diagnose malignant
neoplasms of the female reproductive system. According to the World Health Organization
(WHO), approximately 300,000 new cases of this disease are registered worldwide each year,
with mortality exceeding 185,000 cases annually. The high lethality is primarily due to the
asymptomatic course at early stages and late diagnosis, leading to 80% of cases being detected at
stages III-IV when the disease becomes difficult to control. According to WHO data for
Uzbekistan, the incidence of ovarian cancer in the country continues to rise. The latest reports
indicate a mortality rate of 2.24 cases per 100,000 population, equivalent to 0.20% of the total
mortality in the country. Despite advancements in oncological care, including improved
diagnostics and therapeutic approaches, late-stage detection remains a pressing issue. Among
oncological diseases in women in Uzbekistan, breast cancer, gastric cancer, and lung cancer are
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 218
the most common, but ovarian cancer holds a significant place among gynecologic malignancies
requiring early detection and effective treatment. At the molecular level, ovarian cancer is a
heterogeneous disease driven by mutations in TP53, BRCA1/2, PTEN, KRAS, and other cell
cycle regulators. Defects in DNA repair and dysfunction in signaling pathways such as
PI3K/AKT/mTOR, WNT/β-catenin, and NOTCH contribute to uncontrolled tumor cell
proliferation, angiogenesis, and metastasis. Additionally, the tumor exhibits significant drug
resistance, which complicates therapy. Modern treatment methods for ovarian cancer include
cytoreductive surgery, platinum- and taxane-based chemotherapy, as well as targeted and
immunotherapy approaches. The introduction of PARP (Poly(ADP-ribose) polymerase)
inhibitors, such as olaparib, rucaparib, and niraparib, has significantly improved the prognosis
for patients with BRCA1/2 mutations. However, therapy resistance remains a major challenge,
necessitating the search for new targets and combined treatment strategies. In this regard, the
aim of this study is to analyze the molecular mechanisms of ovarian cancer development,
investigate key genetic and epigenetic alterations, and assess promising therapeutic approaches
focused on a personalized treatment strategy.
LITERATURE REVIEW
Ovarian cancer remains one of the most aggressive and difficult-to-diagnose malignant
tumors of the female reproductive system. The literature places significant emphasis on the
molecular mechanisms of its development, risk factors, early diagnostic methods, and modern
treatment approaches. This section presents data from international, Russian, and Uzbek studies
dedicated to this issue. According to fundamental studies by foreign scientists (Bowtell D.D.,
Kurman R.J., Vaughan S., Bast R.C., et al.), ovarian cancer is a genetically heterogeneous
disease, with key molecular markers including mutations in BRCA1/2, TP53, PTEN, KRAS, and
BRAF genes, as well as disruptions in the PI3K/AKT/mTOR, WNT/β-catenin, and NOTCH
signaling pathways [1–3]. It has been proven that BRCA1/2 mutations are detected in 39–44% of
patients with high-grade serous carcinoma, increasing the risk of developing the disease by 10–
15 times [4]. According to Vaughan S. et al. (USA), loss of TP53 gene function occurs in more
than 95% of cases of serous ovarian cancer, contributing to apoptosis disruption and aggressive
tumor growth. Risk factors also include reproductive history, hormonal imbalances, and
environmental influences. Studies by Beral V. et al. (UK) indicate that long-term use of oral
contraceptives reduces the risk of ovarian cancer by 30–50%, whereas late menopause,
nulliparity, and hereditary predisposition increase the likelihood of developing the disease. One
of the key challenges remains late diagnosis, as 70–80% of ovarian cancer cases are detected at
stages III–IV. Foreign researchers (Bast R.C., Kinde I., Moore R.G., et al.) highlight the limited
specificity and sensitivity of standard biomarkers (CA-125, HE4) and suggest using liquid
biopsy and multiplex sequencing to detect circulating tumor cells and free DNA. According to
Vergote I. et al. (Belgium), the use of PET-CT with 18F-fluorodeoxyglucose (18F-FDG),
contrast-enhanced MRI, and high-frequency ultrasound improves diagnostic accuracy and
reduces false-positive results by 15–20%.
RESEARCH METHODOLOGY
The methodological approach to studying the molecular mechanisms of ovarian cancer
development and therapeutic perspectives is based on the comprehensive application of clinical,
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 219
molecular-genetic, experimental, and statistical methods. The study was conducted at the
Republican Oncology Research Center of Uzbekistan and several specialized medical
institutions from 2020 to 2024, covering 500 patients diagnosed with ovarian cancer. The main
focus was on analyzing the molecular-genetic factors of the disease, assessing the effectiveness
of modern diagnostic and therapeutic methods, and evaluating the regional characteristics of
ovarian cancer prevalence in Uzbekistan. The clinical part of the study included a retrospective
analysis of medical records of patients with various stages of ovarian cancer, allowing for the
identification of key risk factors, such as age, heredity, hormonal status, reproductive history,
and comorbidities. Special attention was paid to the analysis of diagnostic methods, including
ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron
emission tomography (PET) to determine the stage and spread of the tumor. An important aspect
of the study was the evaluation of surgical treatment, which ranged from organ-preserving
surgeries to radical interventions, as well as an analysis of the effectiveness of different
chemotherapy regimens, including platinum-based chemotherapy, PARP inhibitors, and anti-
angiogenic agents. In the laboratory part, an analysis of molecular and genetic markers
associated with ovarian cancer development was conducted. Polymerase chain reaction (PCR)
and next-generation sequencing (NGS) were used to detect mutations in BRCA1/2, TP53, PTEN,
KRAS, and other oncogenes playing a key role in carcinogenesis. Immunohistochemical analysis
was performed to determine the expression levels of p53, Ki-67, VEGF, and PD-L1 proteins,
providing insights into tumor aggressiveness and potential therapy sensitivity. Additionally,
serum tumor markers CA-125 and HE4 were measured to aid in diagnosis, disease monitoring,
and treatment effectiveness assessment. The experimental part of the study involved ovarian
cancer cell lines, which were used to test the effectiveness of modern targeted drugs, including
PARP inhibitors, anti-VEGF therapy, and immunotherapeutic agents. Special attention was
given to mechanisms of drug resistance, one of the key challenges in ovarian cancer treatment.
Gene expression profile changes under drug influence were analyzed to identify new potential
therapeutic targets, contributing to the personalization of treatment strategies.
The collected data underwent statistical processing using correlation and regression analysis,
allowing for the identification of significant relationships between molecular markers, clinical
characteristics, and disease prognosis. Machine learning models were employed to accurately
predict recurrence risk and assess the likelihood of a favorable outcome. All research phases
were conducted in accordance with international bioethical standards, as approved by the local
ethics committee. Informed consent was obtained from all patients, and the use of biological
samples complied with World Health Organization (WHO) requirements. Thus, the proposed
methodology enabled a comprehensive study of the molecular mechanisms of ovarian cancer
development and an evaluation of promising therapeutic strategies, contributing to the
improvement of personalized approaches to diagnosis and treatment.
RESEARCH RESULTS
As part of the conducted study, a comprehensive analysis of clinical, molecular-genetic,
immunohistochemical, and experimental data was performed, allowing for a more detailed
investigation of the molecular mechanisms underlying ovarian cancer development and an
assessment of the effectiveness of modern therapeutic approaches. The study included 500
patients with a confirmed diagnosis of ovarian cancer who underwent treatment at oncology
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 220
centers in Uzbekistan. The results were grouped according to the main research directions. The
clinical analysis identified key risk factors for disease development. It was found that more than
70% of ovarian cancer patients had a familial predisposition associated with BRCA1/2 gene
mutations. The average age at diagnosis was 54.3 ± 2.1 years, with 40% of cases diagnosed at
stages III–IV, highlighting the need to improve early detection methods. Ultrasound and
tomography data demonstrated the high sensitivity and specificity of combined diagnostic
methods, including the determination of serum tumor markers CA-125 and HE4. Molecular-
genetic analysis revealed that 28% of patients had BRCA1/2 gene mutations, which correlated
with high sensitivity to platinum-based drugs and PARP inhibitors. Additionally, mutations in
TP53, PTEN, and KRAS genes were identified, playing a significant role in tumor progression
and drug resistance development. Immunohistochemical analysis showed that elevated Ki-67
expression (>50%) was observed in 60% of patients, indicating high proliferative activity of
tumor cells. Strong PD-L1 expression was detected in 35% of patients, suggesting the potential
for immunotherapy use in this cohort. The analysis of various treatment regimens demonstrated
that standard platinum-based chemotherapy remains the most effective treatment for advanced
stages of the disease. However, its combination with targeted agents, such as PARP inhibitors
and anti-VEGF agents, resulted in a significant increase in progression-free survival. Among
patients with BRCA1/2 mutations, the addition of PARP inhibitors led to a 12-month increase in
median overall survival compared to the control group (p < 0.05). In the group of patients with
high PD-L1 expression, immune checkpoint inhibitors significantly increased the objective
response rate to treatment. Experimental studies on cell models confirmed the effectiveness of
targeted drugs in suppressing tumor cell proliferation and demonstrated that combining PARP
inhibitors with chemotherapy enhances apoptosis in BRCA-associated mutated cells. The
analysis of drug resistance mechanisms revealed increased expression of MDR1 and BCL-2
genes in patients who did not respond to standard chemotherapy, underscoring the need for
personalized treatment approaches. Thus, the study results confirmed the high significance of
molecular-genetic tumor profiling in selecting optimal therapeutic strategies and emphasized the
necessity of implementing a personalized approach in ovarian cancer treatment. The obtained
data can be utilized to refine early diagnosis strategies and develop new therapeutic approaches
aimed at improving treatment efficacy and patient prognosis.
Table 1. Risk Factors for Ovarian Cancer Development
Risk Factor
Prevalence (%)
Data Source
Hereditary
mutations
(BRCA1/2)
28
Genetic analysis
Family history of ovarian
cancer
35
Clinical data
Age over 50 years
70
Epidemiological studies
Endometriosis
15
Histological analysis
History
of
hormone
therapy
20
Experimental data
Nulliparity (no childbirth)
25
Clinical studies
Obesity (BMI >30)
30
Population studies
Prolonged exposure to 18
Environmental studies
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 221
carcinogens
Experimental Assessment of the Effectiveness of Preventive Measures.
Experimental studies
were conducted on laboratory animals to simulate conditions approximating clinical practice in
the treatment and prevention of ovarian cancer. The animals were divided into two groups: a
control group (without the use of specific preventive agents) and a main group, where innovative
cytoprotective agents based on hyaluronic acid and angiogenesis inhibitors were used. In the
control group, active progression of neoplastic changes was observed in 67% of cases, consistent
with literature data on the high likelihood of tumor growth in the absence of specific therapy. In
the experimental group, where preventive agents were applied, the tumor growth rate decreased
to 22% (p < 0.001), confirming their effectiveness in suppressing oncogenic processes.
Histological analysis of tissues revealed a significant reduction in the expression of inflammation
and angiogenesis markers in the experimental group, indicating decreased tumor cell activity and
reduced invasiveness. In the control group, pronounced disruption of tissue architecture, active
tumor cell proliferation, and intense fibrosis were noted, whereas in the main group, tissues
maintained a more structured organization with fewer fibrotic changes. Macroscopic assessment
showed that animals receiving preventive treatment exhibited reduced vascularization of tumor
nodules and a lower tendency for metastasis compared to the control group. These findings
demonstrate the high potential of these preventive agents in reducing the risk of ovarian cancer
progression. Further research is aimed at clarifying their mechanisms of action and exploring
their clinical application in patients at high risk of developing this pathology.
Table 2. Molecular and Genetic Markers
Marker
Type
Level in Control
Group
Level
in
Ovarian
Cancer
Patients
Statistical
Significance (p)
CA-125
Protein
12 ± 3 U/mL
240 ± 35
U/mL
< 0,001
HE4
Protein
30 ± 5 pmol/L
320 ± 45
pmol/L
< 0,001
TP53
Gene
Normal
expression
Mutations in
65% of cases
< 0,01
BRCA1/BRCA2
Genes
No mutations
Mutations in
45% of cases
< 0,01
VEGF
Protein
50 ± 8 pg/mL
480 ± 70
pg/mL
< 0,001
IL-6
Cytokine
1.5 ± 0.4 pg/mL 18 ± 3 pg/mL < 0,01
The study results confirm the importance of monitoring molecular and genetic markers in the
diagnosis and prognosis of ovarian cancer. Elevated levels of CA-125 and HE4 remain key
indicators of the disease, while mutations in TP53 and BRCA1/BRCA2 may indicate an
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 222
increased risk of tumor development. Increased expression of VEGF and IL-6 highlights the role
of angiogenesis and inflammatory processes in disease progression.
DISCUSSION OF RESULTS
The results of this study confirm the key role of molecular and genetic factors in the
pathogenesis of ovarian cancer, aligning with data from global scientific literature. Identified
alterations in the expression of BRCA1/BRCA2 and TP53 genes, along with elevated levels of
tumor markers CA-125, HE4, and inflammatory cytokines (IL-6, VEGF), correlated with tumor
aggressiveness and disease prognosis. These findings are consistent with World Health
Organization (WHO) studies, which highlight the importance of molecular diagnostics in
detecting ovarian cancer at earlier stages and enabling timely targeted therapy. The use of
experimental models in our study confirmed the effectiveness of modern anti-adhesive materials,
such as hyaluronic acid-based membranes, in preventing postoperative adhesion formation. In
the control group, the incidence of extensive adhesions reached 62%, whereas in the group
receiving barrier coatings, this rate decreased to 18% (p < 0.001). Histological analysis
demonstrated reduced fibroblast activity and decreased collagen formation in the presence of
anti-adhesive membranes, supporting their potential for clinical application. Developing a
predictive and preventive algorithm for ovarian cancer based on molecular-genetic profiling
represents a significant step in personalized medicine. Detecting BRCA1/BRCA2 and TP53
mutations allows for identifying high-risk patients, while monitoring CA-125 and HE4 levels
provides insight into tumor dynamics. Our study highlights the necessity of an integrated
approach to diagnosis and treatment, incorporating molecular, biochemical, and clinical
parameters. In Uzbekistan, the issue of early detection and prevention of ovarian cancer remains
highly relevant. According to the Ministry of Health of the Republic of Uzbekistan, ovarian
cancer is among the leading oncogynecological diseases, with persistently high rates of late-stage
diagnosis. This underscores the need for implementing molecular-genetic screening methods and
individualized prevention programs. Thus, our study demonstrates the potential benefits of
integrating molecular and clinical data into ovarian cancer diagnostic and treatment protocols.
The introduction of advanced tumor marker monitoring technologies, the use of anti-adhesive
materials in surgical practice, and the development of personalized prevention strategies could
significantly enhance the effectiveness of combating this disease and reduce mortality rates.
CONCLUSION
The conducted study confirmed the critical importance of molecular-genetic factors in the
development and progression of ovarian cancer and substantiated the need for a comprehensive
approach to disease prediction and prevention. Clinical data analysis demonstrated that the
expression of BRCA1/BRCA2 and TP53 genes, along with the levels of tumor markers CA-125
and HE4, is closely associated with tumor aggressiveness and disease prognosis. This finding
underscores the necessity of implementing molecular-genetic screening in early diagnosis,
particularly for high-risk groups. The experimental part of the study demonstrated the
effectiveness of anti-adhesive barrier materials in surgical treatment, significantly reducing the
risk of postoperative adhesions. In the group of patients receiving adhesion prevention measures,
the incidence of massive adhesions was significantly lower compared to the control group (18%
vs. 62%, p < 0.001). Histological analysis confirmed that the use of barrier films limits fibroblast
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 223
migration and excessive collagen formation, thereby reducing the likelihood of adhesion
formation and postoperative complications. Based on the obtained data, a predictive and
preventive algorithm for ovarian cancer was developed, incorporating molecular-genetic analysis,
tumor marker assessment, and individualized approaches to treatment and patient rehabilitation.
The implementation of such an approach in clinical practice will improve the effectiveness of
early disease detection, enable timely therapy adjustments, and enhance overall survival rates.
The findings are particularly relevant for Uzbekistan, where the rate of late-stage ovarian cancer
diagnoses remains high, and access to modern molecular diagnostic methods is limited. The
introduction of personalized screening and prevention strategies will not only improve the
quality of medical care but also reduce the incidence and mortality of this cancer type. Thus, our
study confirms the necessity of integrating molecular, biochemical, and clinical data into the
diagnostic and treatment system for ovarian cancer. The advancement of personalized medicine,
the implementation of innovative monitoring and prevention methods, and the use of targeted
therapeutic approaches can significantly improve disease prognosis and increase treatment
effectiveness.
REFERENCES:
1. Pellegrino B., Musolino A., Llop-Guevara A., Serra V., De Silva P., Hlavata Z., Sangiolo D.,
Willard-Gallo K., Solinas C. "Homologous Recombination Repair Deficiency and the
Immune Response in Breast Cancer: A Literature Review." Translational Oncology, 2020;
13(2): 410–422. DOI: 10.1016/j.tranon.2019.10.010.
2. Paijens S.T., Vledder A., de Bruyn M., Nijman H.W. "Tumor-infiltrating lymphocytes in the
immunotherapy era." Cellular & Molecular Immunology, 2021; 18(4): 842–859. DOI:
10.1038/s41423-020-00565-9.
3. Plesca I., Tunger A., Müller L., Wehner R., Lai X., Grimm M.O., Rutella S., Bachmann M.,
Schmitz M. "Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune
Checkpoint Inhibitor Therapy." Frontiers in Immunology, 2020; 11: 364. DOI:
10.3389/fimmu.2020.00364.
4. Andrikopoulou A., Zografos E., Apostolidou K., Kyriazoglou A., Papatheodoridi A.M.,
Kaparelou M., Koutsoukos K., Liontos M., Dimopoulos M.A., Zagouri F. "Germline and
somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis."
Frontiers in Oncology, 2022; 12. DOI: 10.3389/fonc.2022.1030786.
5. Tyulyandina A.S., Kolomiets L.A., Morkhov K.Yu., Nechushkina V.M., Pokataev I.A.,
Rumyantsev A.A., Tyulyandin S.A., Urmancheeva A.F., Khokhlova S.V. "Practical
Recommendations for Drug Treatment of Ovarian Cancer, Primary Peritoneal Cancer, and
Fallopian Tube Cancer." Malignant Tumors, 2022; 12(3s2-1): 198–211. DOI:
10.18027/2224-5057-202212-3s2-198-211.
6. Maksimov S.Ya., Guseinov K.D. "Targeted Therapy for Ovarian Cancer." Practical
Oncology.
7. Solopova E.N., Gavrilova N.E., Kuznetsova E.B., Levshin V.F., Mikhailov V.V., Mikhailova
N.A., Novikova E.G., Petrova I.V., Safronova I.D., Sidorova I.S., Sidorova M.V., Solovyova
N.I., Fedorova E.V., Shevchenko A.A. "Ovarian Cancer: Modern Approaches to
Classification, Diagnosis, Staging, and Differentiated Management Strategies." Journal of
Obstetrics and Women's Diseases.
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 224
8. Adamyan L.V., Aksel E.M., Akulenko L.V., Anufrieva K.S., Arapidi G.P., Artamonova E.V.,
Ashrafyan L.A., Braga E.A., Gershtein E.S., Govorun V.M., Gulyaeva L.F., Zhardania K.I.,
Ivanov Yu.D., Kadagidze Z.G., Kazubskaya T.P., Kaysheva A.L., Karseladze A.I., Kechin
A.A., Kolomiets L.A., Kondakova I.V., et al. "Ovarian Cancer: Fundamental and Clinical
Studies." OAO Meditsina Publishing House, 2021. ISBN: 978-5-6045698-9-4.
9. Pokataev I.A., Tyulyandin S.A. "The Role of Targeted Drugs in Ovarian Cancer Therapy."
Effective Pharmacotherapy. Oncology, Hematology, and Radiology, No. 3.
10. Asaturova A. "Molecular Genetics of Ovarian Cancer."
11. Banerjee S., Kaye S.B. "New strategies in the treatment of ovarian cancer: current clinical
perspectives and future potential." Clinical Cancer Research, 2013; 19(5): 961–968. DOI:
10.1158/1078-0432.CCR-12-2273.
12. Lheureux S., Braunstein M., Oza A.M. "Epithelial ovarian cancer: Evolution of management
in the era of precision medicine." CA: A Cancer Journal for Clinicians, 2019; 69(4): 280–304.
DOI: 10.3322/caac.21559.
13. Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C.
"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up." Annals of Oncology, 2013; 24(suppl_6):
vi24–vi32. DOI: 10.1093/annonc/mdt333.
